Cancer ResearchResearch PaperOpen Access

Everolimus or chemotherapy first for pancreatic neuroendocrine tumors? SEQTOR trial finds no PFS winner

In 141 patients with advanced pancreatic NETs, everolimus and STZ/5-FU gave similar progression-free survival, but chemotherapy shrank tumors far more often.

Wednesday, November 18, 2026 0 views
Published in ESMO Open
oncologist reviewing abdominal CT scan of liver metastases on a monitor beside a patient consultation desk

Summary

The SEQTOR trial asked which of two standard drugs should come first for advanced pancreatic neuroendocrine tumors: everolimus (a pill that blocks the mTOR growth pathway) or streptozotocin plus 5-fluorouracil chemotherapy. In 141 randomized patients, the share without progression at 12 months was not significantly different (71.4% everolimus first vs 61.8% chemotherapy first). Chemotherapy shrank tumors much more often (30.3% vs 11.6% in first line). Overall survival did not differ significantly. Everolimus caused more mouth sores, skin problems, high blood sugar and pneumonitis, and more dose changes. The trial was underpowered for its original sequencing question after the primary endpoint was changed, so treatment choice should be individualized.

Detailed Summary

Pancreatic neuroendocrine tumors (panNETs) are rare, often slow-growing cancers. Two approved drugs, everolimus (an mTOR inhibitor) and streptozotocin plus 5-fluorouracil (STZ/5-FU), have never been compared head to head, and the best order of use was unknown. SEQTOR is the first randomized trial to test this, so its data help guide a common decision.

This was an international, open-label, randomized, crossover phase III trial run across eight countries. Adults with unresectable or metastatic, well-differentiated grade 1-2 panNET received everolimus 10 mg/day and then STZ/5-FU at progression (n = 72), or the reverse (n = 69). Of 141 randomized, 135 were treated and 51.1% reached second-line therapy. About 84% had grade 2 tumors and 93% had metastases.

The original primary endpoint was 35-month PFS across both lines. Because of slow accrual (partly due to PRRT approval) and long survival, it was amended to 12-month PFS on first-line treatment. That rate was 71.4% with everolimus and 61.8% with STZ/5-FU (OR 0.65, 95% CI 0.32-1.32, P = 0.229). Median PFS1 was 19.4 vs 22.7 months (HR 1.16, P = 0.474). Blinded central review agreed. Median overall survival was 61.7 vs 50.6 months (HR 1.43, 95% CI 0.86-2.37), not significant.

Response rates favored chemotherapy: 30.3% vs 11.6% in first line (P = 0.012; central review 30.2% vs 10.3%) and 30.6% vs 9.1% in second line (P = 0.072). Median duration of response was 25.2 months with STZ/5-FU vs 4.5 months with everolimus. Exploratory subgroup analyses suggested chemotherapy responses were higher in younger patients, ECOG 0 and grade 2 tumors, while grade 1 tumors fared better with everolimus (12-month PFS 100% vs 80.8%). Treatment-naive patients had 18-month OS of 93.6% vs 77.5% favoring everolimus first (HR 2.5).

Safety differed in kind. Everolimus caused more oral mucositis, rash, hyperglycemia and edema; pneumonitis occurred in 7% first line and 21% second line. STZ/5-FU caused more nausea, and grade 1-2 renal failure in 13.4% of first-line patients. Grade 3 or higher toxicity was 55.1% with everolimus vs 43.9% with STZ/5-FU first line. Dose delays or reductions occurred in 59.4% vs 13.6%. No toxic deaths occurred.

The authors conclude both drugs are valid and sequencing should be tailored by tumor grade, performance status, comorbidities and toxicity. Key caveats: the trial failed to answer its sequencing question, the endpoint was changed mid-study, it was open-label and underpowered, and subgroup findings are hypothesis-generating. PRRT was approved after the trial began and was not tested here.

Key Findings

  • 12-month PFS on first line: 71.4% everolimus vs 61.8% STZ/5-FU (OR 0.65, 95% CI 0.32-1.32, P = 0.229), not significantly different; 141 patients randomized
  • Median PFS1 19.4 vs 22.7 months (HR 1.16, P = 0.474); median overall survival 61.7 vs 50.6 months (HR 1.43, 95% CI 0.86-2.37), a null
  • First-line ORR 30.3% with STZ/5-FU vs 11.6% with everolimus (P = 0.012); median response duration 25.2 vs 4.5 months
  • Second-line ORR 30.6% STZ/5-FU vs 9.1% everolimus (P = 0.072, not significant)
  • Everolimus: more mucositis, rash, hyperglycemia, edema; pneumonitis 7% first line and 21% second line; dose delays/reductions 59.4% vs 13.6% (P < 0.001)
  • STZ/5-FU: more nausea; grade 1-2 renal failure in 13.4% first line; grade 3+ toxicity 55.1% everolimus vs 43.9% STZ/5-FU first line; no toxic deaths
  • Exploratory: grade 1 tumors 12-month PFS 100% everolimus vs 80.8% STZ/5-FU; treatment-naive 18-month OS 93.6% vs 77.5% favoring everolimus first

Methodology

International, open-label, randomized (1:1, stratified by ECOG-PS), crossover phase III trial in 8 countries, June 2014 to July 2021, with 141 patients randomized and 135 treated. The primary endpoint was changed from 35-month PFS1+2 to 12-month PFS1 because of slow accrual, with investigator and blinded central review (RECIST 1.0). Analyses used Kaplan-Meier, Cox and logistic regression, and Fisher's exact test; median follow-up was 36.6 months. Subgroup analyses were multivariable and exploratory.

Study Limitations

The trial was underpowered for sequencing after the primary endpoint was amended, was open-label, and subgroup analyses were exploratory with small numbers and wide confidence intervals. PRRT, now approved, was not part of the comparison, and few patients received concurrent somatostatin analogs. Authors note imbalances at baseline (e.g., quality of life, prior treatments) and used RECIST 1.0; conflicts of interest were not detailed in the text provided.

Enjoyed this summary?

Get the latest longevity research delivered to your inbox every week.

Enter your email to subscribe: